Vnitr Lek 1996, 42(4):239-245

[Personal experience with 200mg of micronized fenofibrate (Lipanthyl 200 M) in the treatment of primary dyslipidemias].

H Vaverková, D Novotný, L Ficker
III. Interní klinika FN, Olomouc.

Micronized phenofibrate 200 mg was administered in clinical trial to 30 patients with dyslipidaemia. Their average age was 51.9 years (10 with type 2a, 12 with type 2b and 8 with types 4 and 5). After 12 weeks of treatment significant improvement of the whole lipid profile was achieved. The total cholesterol declined in different sub-groups by 16, 17 and 20% resp. LDL cholesterol declined by 20 and 18 per cent in types 2a and 2b, in types 4 and 5 it was not assessed (it was not possible to use Friedewald's equation). Triglycerides declined by 39, 45 and 75%. The HDL concentration increased by 16, 27 and 25%. The atherogenic indexes TCh/HDL-Ch declined by 28, 36 and 32%. LDL-Ch/HDL-Ch dropped by 30 and 34%. The extent of the hypolipidaemic effect depended on the baseline value: the more pathological the baseline value, the more marked the improvement. As to other investigated indicators there was a significant rise of the apolipoprotein AI and Lp AI particle concentration. Apoprotein B declined insignificantly. Uric acid declined significantly by 28%. Fibrinogen dropped significantly only in type 2a. The lipoprotein(a) concentration did not change significantly. The drug was very well tolerated and undesirable effects were minimal. Micronized phenofibrate (Lipanthyl 200 M) due to its comprehensive favourable effect on the entire lipid profile and other risk factors can prove useful in the treatment of all types of dyslipidaemias (with the exception of type I). As compared with Lipanthyl 100, the better pharmacokinetic properties make it possible to reduce the dose from 300 mg/day and it can be administered in a single daily dose.

Keywords: Dosage Forms; Female; Fenofibrate, administration & dosage, ; Humans; Hyperlipidemias, blood, ; Hypolipidemic Agents, administration & dosage, ; Male; Middle Aged; Particle Size

Published: April 1, 1996  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vaverková H, Novotný D, Ficker L. [Personal experience with 200mg of micronized fenofibrate (Lipanthyl 200 M) in the treatment of primary dyslipidemias]. Vnitr Lek. 1996;42(4):239-245.
Download citation




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.